Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • Connecticut
  • New Haven


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • The Effect of Lactation on Insulin Sensitivity and Lipolysis in Women
    NCT04146909
    Conditions:   GDM;   Lactation
    Intervention:   Diagnostic Test: Hyperinsulinemic-euglycemic clamp
    Sponsors:   Yale University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
    NCT04135560
    Condition:   Dermatitis Atopic
    Interventions:   Drug: PF-07038124 and Vehicle;   Drug: PF-07038124 or vehicle
    Sponsor:   Pfizer
    Recruiting
  • Perinatal Attentional Retraining Intervention for Smoking for Minority Women
    NCT04114877
    Condition:   Postpartum Smoking Relapse
    Interventions:   Behavioral: Attentional retraining (AR);   Behavioral: Visual probe (VP)
    Sponsors:   Yale University;   National Institute on Minority Health and Health Disparities (NIMHD)
    Recruiting
  • A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.
    NCT04111614
    Condition:   Healthy
    Interventions:   Drug: Tofacitinib tablet;   Drug: Tofacitinib Oral Solution
    Sponsor:   Pfizer
    Recruiting
  • A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy Participants
    NCT04090047
    Condition:   Heathy Participants
    Interventions:   Drug: PF-06700841;   Drug: Itraconazole
    Sponsor:   Pfizer
    Recruiting
  • Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation
    NCT04065633
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: P3-Fast;   Drug: Comm-Fast;   Drug: Vari-Fast;   Drug: Comm-Fed
    Sponsor:   Pfizer
    Recruiting
  • Guanfacine to Improve Substance Use Outcomes in Women
    NCT03980184
    Condition:   Substance Use Disorders
    Interventions:   Drug: Guanfacine;   Other: placebo
    Sponsor:   Yale University
    Recruiting
  • Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
    NCT03946111
    Conditions:   Binge-Eating Disorder;   Obesity
    Interventions:   Drug: Naltrexone and Bupropion;   Other: Placebo
    Sponsor:   Yale University
    Recruiting
  • Transcranial Direct Current Stimulation and Fear Extinction
    NCT03907917
    Condition:   Anxiety Disorders
    Intervention:   Device: tDCS
    Sponsors:   Yale University;   National Institute of Mental Health (NIMH)
    Recruiting
  • Neuroimmune Effects of Opioid Administration
    NCT03801629
    Conditions:   Microgliosis;   Drug Effect
    Intervention:   Drug: Intramuscular Morphine
    Sponsor:   Yale University
    Recruiting
  • The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.
    NCT03752918
    Condition:   Post Traumatic Stress Disorder
    Interventions:   Drug: MDMA;   Drug: Niacin
    Sponsor:   Yale University
    Recruiting
  • Influence of Medication on Functional Connectivity
    NCT03612713
    Condition:   Prescription Drug Abuse (Not Dependent)
    Interventions:   Drug: Oxycodone Medication First;   Drug: Placebo First
    Sponsors:   Yale University;   National Institute on Drug Abuse (NIDA)
    Recruiting
  • Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
    NCT03587649
    Conditions:   Alzheimer Disease;   Parkinson Disease;   Healthy Volunteers
    Intervention:   Drug: [18F]MNI-1126
    Sponsor:   Invicro
    Recruiting
  • CB1R in Synthetic Psychoactive Cannabinoids
    NCT03539575
    Condition:   Drug Dependence
    Intervention:   Other: [11-C]OMAR
    Sponsors:   Yale University;   National Institutes of Health (NIH);   National Institute on Drug Abuse (NIDA)
    Recruiting
  • Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET
    NCT03527485
    Conditions:   Opiate Dependence;   Cocaine Dependence
    Intervention:   Diagnostic Test: 11UCB-J PET Scan
    Sponsor:   Yale University
    Recruiting
  • Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
    NCT03500484
    Conditions:   Obesity, Childhood;   Neural Development
    Intervention:   Drug: Liraglutide
    Sponsor:   Yale University
    Recruiting
  • Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.
    NCT03356483
    Condition:   Obsessive-Compulsive Disorder
    Interventions:   Drug: Psilocybin (0.25mg/kg);   Drug: Niacin (250mg)
    Sponsors:   Yale University;   Heffter Research Institute
    Recruiting
  • Mavoglurant in Alcohol Drinking
    NCT03327792
    Condition:   Alcohol Drinking
    Interventions:   Drug: Mavoglurant;   Drug: Placebo
    Sponsor:   Yale University
    Recruiting
  • The Neural Correlates of Cannabis Use
    NCT03104257
    Conditions:   Cannabis Dependence;   Healthy
    Intervention:   Other: [11-C]OMAR
    Sponsors:   Yale University;   National Institute on Drug Abuse (NIDA)
    Recruiting
  • Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD
    NCT03103750
    Condition:   ADHD
    Interventions:   Procedure: Magnetic Resonance Imaging (MRI);   Drug: Raclopride;   Dietary Supplement: calcitriol;   Drug: Placebo oral capsule;   Procedure: high-resolution research tomography;   Drug: Dextro Amphetamine
    Sponsors:   Yale University;   Brain & Behavior Research Foundation
    Recruiting
  • Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS
    NCT02124941
    Conditions:   Cocaine Dependence;   Healthy
    Interventions:   Drug: N-acetyl cysteine;   Diagnostic Test: [18F]FDG PET scan;   Diagnostic Test: 1H MRS;   Diagnostic Test: [11C]APP311 PET scan
    Sponsor:   Yale University
    Recruiting
  • Ketamine in Borderline Personality Disorder
    NCT03395314
    Condition:   Borderline Personality Disorder
    Interventions:   Drug: Ketamine;   Drug: Midazolam
    Sponsors:   Yale University;   Nathan Kline Institute for Psychiatric Research;   American Foundation for Suicide Prevention
    Recruiting
  • Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
    NCT01730781
    Conditions:   Schizophrenia;   Cannabis Dependence;   Prodromal for Psychotic Illness;   Family History of Alcoholism;   Healthy Control
    Intervention:   Radiation: [11-C]OMAR
    Sponsors:   Yale University;   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH)
    Recruiting
  • Imaging the Neurochemistry of Drug Addiction With PET
    NCT02817698
    Conditions:   Smoking;   Cannabis
    Intervention:   Drug: cannabis
    Sponsor:   Yale University
    Recruiting
  • Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
    NCT02008292
    Conditions:   Smoking;   Schizophrenia
    Intervention:   Drug: Physostigmine
    Sponsors:   Yale University;   National Institutes of Health (NIH);   National Institute on Drug Abuse (NIDA)
    Recruiting
  • Evaluating the Feasibility and Efficacy of a Real-time Smoking Intervention Using Wearable Technology
    NCT04172623
    Condition:   Tobacco Use Cessation
    Interventions:   Behavioral: Real-Time Smoking Intervention;   Behavioral: Standard Treatment
    Sponsors:   Yale University;   Patterson Trust Mentored Research Award: Clinical, Health Services and Policy Research
    Recruiting
  • Examining the Effect of Burosumab on Muscle Function
    NCT04146935
    Condition:   X-linked Hypophosphatemia
    Intervention:   Drug: Burosumab Injection [Crysvita]
    Sponsor:   Yale University
    Recruiting
  • Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
    NCT04141150
    Conditions:   Alzheimer's Disease;   Mild Cognitive Impairment Due to Alzheimer's Disease;   Healthy Volunteers
    Intervention:   Drug: [18F]APN-1607
    Sponsor:   Aprinoia Therapeutics Inc.
    Recruiting
  • Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
    NCT04131829
    Condition:   Obsessive-Compulsive Disorder
    Interventions:   Drug: Fluoxetine - immediate treatment;   Drug: Fluoxetine - delayed treatment
    Sponsors:   Yale University;   National Institute of Mental Health (NIMH)
    Recruiting
  • The Recovery in Stroke Using PAP Study
    NCT04130503
    Conditions:   Ischemic Stroke;   Obstructive Sleep Apnea
    Interventions:   Device: PAP;   Behavioral: HLE
    Sponsors:   Yale University;   Hartford HealthCare
    Recruiting
  • Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
    NCT04057807
    Condition:   Alzheimer Disease
    Intervention:   Drug: LPS
    Sponsor:   Yale University
    Recruiting
  • Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study
    NCT04057001
    Conditions:   Liver Transplant; Complications;   Hepatitis C
    Intervention:  
    Sponsor:   Yale University
    Recruiting
  • GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
    NCT04051996
    Condition:   ACUTE MYELOID LEUKEMIA
    Interventions:   Drug: Glasdegib;   Drug: Decitabine
    Sponsors:   Yale University;   Pfizer Inc., U.S. Pharmaceuticals Group
    Recruiting
  • Detection of Postoperative Respiratory Depression in High Risk Patients Utilizing Minute Ventilation Monitoring
    NCT04017702
    Condition:   Respiratory Depression
    Intervention:   Device: Expiron respirator
    Sponsor:   Yale University
    Recruiting
  • Impact of Cigarette and E-cigarette Flavors on Adult Smoking Behavior
    NCT04009850
    Condition:   Tobacco Use
    Interventions:   Other: Cigarette Brand Switching;   Other: E-cigarette Flavor
    Sponsors:   Yale University;   National Institute on Drug Abuse (NIDA);   Food and Drug Administration (FDA)
    Recruiting
  • SV2 PET Imaging With [11C]APP311
    NCT03995121
    Conditions:   Schizophrenia and Other Psychotic Disorders;   Cannabis Use Disorder;   Healthy
    Intervention:   Radiation: [11C]APP311
    Sponsor:   Yale University
    Recruiting
  • Ivabradine for Rate Control in Permanent Atrial Fibrillation
    NCT03987204
    Conditions:   Atrial Fibrillation;   Atrial Fibrillation, Persistent
    Intervention:   Drug: Ivabradine
    Sponsor:   Yale University
    Recruiting
  • Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease
    NCT03978156
    Condition:   Sickle Cell Disease
    Interventions:   Drug: Dronabinol;   Drug: Placebo oral tablet
    Sponsor:   Yale University
    Recruiting
  • Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty
    NCT03977454
    Condition:   Hip Arthropathy
    Interventions:   Procedure: Nerve Block;   Procedure: Periarticular Injection (PAI);   Drug: Ropivacaine;   Drug: Dex
    Sponsor:   Yale University
    Recruiting
  • A Study of the Effects of LY3372689 on the Brain in Healthy Participants
    NCT03944031
    Condition:   Healthy
    Interventions:   Drug: LY3372689;   Diagnostic Test: [18F]LSN3316612
    Sponsor:   Eli Lilly and Company
    Recruiting
  • Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients
    NCT03872141
    Conditions:   Breast Cancer;   Chemotherapy Induced Peripheral Neuropathy;   Paclitaxel Induced Neuropathy
    Intervention:   Diagnostic Test: Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer
    Sponsor:   Yale University
    Recruiting
  • Risk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure
    NCT03845660
    Condition:   Heart Failure
    Intervention:   Behavioral: Electronic Alert
    Sponsor:   Yale University
    Recruiting
  • Creation of a Digital Heart Failure Registry Using a Novel Mobile Health Platform: HUGO-HF
    NCT03810638
    Condition:   Heart Failure
    Intervention:  
    Sponsor:   Yale University
    Recruiting
  • The EXPLORE MG Registry for Myasthenia Gravis
    NCT03792659
    Condition:   Myasthenia Gravis
    Intervention:   Other: Blood Sample Draw
    Sponsor:   Yale University
    Recruiting
  • Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders
    NCT03764098
    Condition:   Alcohol Use
    Interventions:   Drug: Guanfacine ER;   Other: Placebo
    Sponsors:   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Recruiting
  • Stress Reduction Study for Partners of Early Stage Dementia
    NCT03691428
    Condition:   Dementia Caregiving
    Intervention:   Behavioral: Wish Outcome Obstacle Plan
    Sponsors:   Yale University;   National Institute on Aging (NIA)
    Recruiting
  • Daytime Bright Light, Circadian Abnormalities, and Delirium in Medical ICU Patients
    NCT03684460
    Condition:   Circadian Rhythm Disorders
    Interventions:   Device: Daytime Bright Light;   Device: Usual Light
    Sponsor:   Yale University
    Recruiting
  • Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis
    NCT03684187
    Condition:   Primary Biliary Cholangitis
    Intervention:   Behavioral: Mindfulness Based Intervention
    Sponsor:   Yale University
    Recruiting
  • Effect of Mental Imagery Training on Brain Plasticity and Motor Function in Individuals With Parkinson's Disease
    NCT03623386
    Condition:   Parkinson Disease
    Interventions:   Other: PD neurofeedback;   Other: PD control
    Sponsor:   Yale University
    Recruiting
  • Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?
    NCT03588754
    Condition:   Alcohol Drinking
    Interventions:   Drug: Propranolol;   Drug: Placebo
    Sponsors:   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Recruiting
  • The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants
    NCT03535883
    Conditions:   Pleural Effusion;   Thoracic Effusion
    Intervention:   Drug: Novel Oral Anti-Coagulants
    Sponsor:   Yale University
    Recruiting
  • APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
    NCT03502330
    Conditions:   Advanced Melanoma;   Non-small Cell Lung Cancer;   Renal Cell Carcinoma
    Interventions:   Drug: APX005M;   Drug: Cabiralizumab;   Drug: Nivolumab
    Sponsors:   Yale University;   Bristol-Myers Squibb;   Apexigen, Inc.
    Recruiting
  • CBT4CBT With Spanish Alcohol Users
    NCT03474588
    Condition:   Alcohol Use Disorder
    Interventions:   Behavioral: Standard treatment (ST) PLUS web-based CBT4CBT;   Behavioral: Standard Treatment (ST)
    Sponsors:   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Recruiting
  • Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure
    NCT03446651
    Condition:   Heart Failure
    Interventions:   Drug: Lysine Chloride;   Other: Placebo
    Sponsor:   Yale University
    Recruiting
  • Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.
    NCT03410654
    Condition:   Kidney Transplant; Complications
    Intervention:   Drug: Tacrolimus, Extended Release, (Envarsus Xr)
    Sponsor:   Yale University
    Recruiting
  • Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
    NCT03367533
    Condition:   Depressive Disorder, Major
    Interventions:   Drug: Ketamine;   Drug: Perampanel;   Drug: Placebo
    Sponsor:   Yale University
    Recruiting
  • An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis
    NCT03359174
    Condition:   Cholangitis, Sclerosing
    Intervention:   Drug: All-trans retinoic acid
    Sponsor:   Yale University
    Recruiting
  • Lifestyle, Exercise, and Nutrition Study Early After Diagnosis
    NCT03314688
    Condition:   Breast Neoplasms
    Interventions:   Behavioral: Dietary/Physical Activity intervention;   Behavioral: Usual Care
    Sponsor:   Yale University
    Recruiting
  • Patient Driven Recovery With Nalmefene and Coaching
    NCT03279562
    Conditions:   Opioid-use Disorder;   Harmful; Use, Alcohol
    Intervention:   Drug: Nalmefene
    Sponsors:   Yale University;   First Pavlov State Medical University in St. Petersburg, Russia
    Recruiting
  • Pregnancy, Mindfulness, and Massage
    NCT03276208
    Conditions:   Tobacco Use;   Pregnancy Related
    Interventions:   Other: Prenatal Massage;   Other: Mindfulness
    Sponsors:   Yale University;   Massage Therapy Foundation
    Recruiting
  • Toradol to Reduce Ureteroscopic Symptoms Trial
    NCT03111381
    Conditions:   Urinary Lithiasis;   Kidney Diseases;   Kidney Stone;   Pain, Postoperative
    Intervention:   Drug: Toradol
    Sponsor:   Yale University
    Recruiting
  • Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
    NCT03071224
    Conditions:   Alzheimer Disease;   Healthy Volunteers
    Interventions:   Drug: [18F] MNI-946;   Drug: [18F]Florbetapir
    Sponsor:   Invicro
    Recruiting
  • Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
    NCT02979977
    Condition:   Squamous Cell Cancers of the Head and Neck
    Interventions:   Drug: cetuximab;   Drug: afatinib
    Sponsors:   Yale University;   National Comprehensive Cancer Network;   Boehringer Ingelheim
    Recruiting
  • Oxytocin and Brain Responses in Maternal Addiction
    NCT02979093
    Condition:   Maternal Behavior
    Interventions:   Drug: Oxytocin;   Drug: Placebos
    Sponsors:   Lane Strathearn, MBBS PhD;   Yale University
    Recruiting
  • Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
    NCT02899793
    Condition:   Recurrent Endometrial Cancer
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Yale University;   Merck Sharp & Dohme Corp.
    Recruiting
  • Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
    NCT02864147
    Conditions:   Cervical Intraepithelial Neoplasia;   Cervical Dysplasia
    Interventions:   Drug: 9-valent HPV vaccine;   Drug: Imiquimod
    Sponsor:   Yale University
    Recruiting
  • Pilot: Feasibility of Intermittent Enteral Feeding in Ventilated MICU Patients
    NCT04164108
    Condition:   Nutrition
    Intervention:   Dietary Supplement: Intermittent Enteral Nutrition Protocol
    Sponsor:   Yale University
    Recruiting
  • Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes
    NCT04101045
    Conditions:   Type 1 Diabetes;   De Novo Lipogenesis
    Intervention:   Diagnostic Test: Oral Glucose Tolerance Test
    Sponsors:   Yale University;   Juvenile Diabetes Research Foundation
    Recruiting
  • Active Surveillance of the Small Renal Mass
    NCT02204800
    Condition:   Small Renal Mass, Kidney Cancer
    Intervention:  
    Sponsor:   Yale University
    Recruiting
  • Window Trial 5-aza in HNSCC, T-tare
    NCT02178072
    Condition:   Head and Neck Squamous Cell Carcinoma
    Intervention:   Drug: 5-Azacitadine
    Sponsor:   Yale University
    Recruiting
  • Mechanisms of Obesity and Its Metabolic Complications in Youth
    NCT03454828
    Condition:   Obesity, Childhood
    Interventions:   Dietary Supplement: obese carbohydrate diet;   Dietary Supplement: lean carbohydrate diet
    Sponsor:   Yale University
    Recruiting
  • Brain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART)
    NCT03183388
    Condition:   Mood Disorders
    Intervention:   Behavioral: BE-SMART
    Sponsors:   Yale University;   National Institute of Mental Health (NIMH)
    Recruiting
  • Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes
    NCT02693938
    Condition:   Type 1 Diabetes
    Interventions:   Device: Follicular Euglycemic clamp;   Device: Luteal Euglycemic clamp
    Sponsors:   Yale University;   The Leona M. and Harry B. Helmsley Charitable Trust
    Recruiting
  • Comparison Between Gastric Band, Laparoscopic Sleeve Gastrectomy, Gastric Bypass Surgeries
    NCT02004561
    Condition:   Obese Adolescents
    Intervention:  
    Sponsor:   Yale University
    Recruiting
  • Hepatic De Novo Lipogenesis (DNL)in the Pathogenesis of Hepatic Steatosis in Obese Youth
    NCT01725035
    Conditions:   Hepatic Steatosis;   Fatty Liver
    Intervention:  
    Sponsors:   Yale University;   American Heart Association;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
    NCT03093155
    Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Drug: Ixabepilone;   Drug: Bevacizumab
    Sponsors:   Yale University;   R-Pharm-US, LLC
    Recruiting
  • Gain-framed Messages and NRT for Lung Cancer Screening Patients
    NCT03069924
    Conditions:   Lung Cancer Screening;   Smoking Cessation
    Interventions:   Behavioral: Gain-framed messaging;   Drug: Nicotine replacement therapy;   Combination Product: Gain-framed messaging plus NRT;   Behavioral: Counseling alone
    Sponsors:   Medical University of South Carolina;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
    NCT02681549
    Conditions:   Melanoma;   Non-small Cell Lung Cancer;   Brain Metastasis
    Intervention:   Drug: Pembrolizumab plus Bevacizumab
    Sponsor:   Yale University
    Recruiting
  • A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
    NCT02665143
    Condition:   Relapsed/Refractory Acute Myeloid Leukemia
    Interventions:   Drug: nintedanib and AML induction;   Drug: AML induction (placebo)
    Sponsors:   Yale University;   Vanderbilt University
    Recruiting
  • Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP)
    NCT02658032
    Conditions:   Smoking Cessation;   Biofeedback
    Interventions:   Behavioral: personalized cessation care;   Behavioral: bio feedback;   Other: standard care
    Sponsor:   Yale University
    Recruiting
  • Patient and Parent Preferences for an On-Body Automated Insulin Delivery System
    NCT03534544
    Condition:   Diabetes Mellitus, Type 1
    Intervention:  
    Sponsors:   Joslin Diabetes Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • Efficacy and Mechanisms of CBT4CBT for Alcohol Use Disorders
    NCT02742246
    Condition:   Alcohol Use Disorder
    Interventions:   Behavioral: Individual clinician-provided CBT;   Behavioral: CBT4CBT
    Sponsor:   Yale University
    Recruiting
  • HLAB-002 of ANS-6637 for Alcohol Use Disorder
    NCT03970109
    Condition:   Alcohol Use Disorder
    Interventions:   Drug: ANS-6637;   Drug: Placebo oral tablet
    Sponsor:   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Recruiting
  • Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
    NCT03586297
    Condition:   Triple Negative Breast Cancer
    Intervention:  
    Sponsors:   Hackensack Meridian Health;   Breast Cancer Research Foundation
    Recruiting
  • Nutrition and Prostate Cancer
    NCT03532308
    Condition:   Prostate Cancer
    Interventions:   Drug: Fermented Soy;   Other: Placebo
    Sponsor:   Yale University
    Recruiting
  • A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
    NCT03410875
    Conditions:   Hairy Cell Leukemia;   Leukemia;   Leukemia, Hairy Cell
    Interventions:   Drug: Vemurafenib;   Drug: Obinutuzumab
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Dana-Farber Cancer Institute;   Yale University
    Recruiting
  • Maraviroc to Augment Rehabilitation Outcomes After Stroke
    NCT03172026
    Condition:   Stroke
    Interventions:   Drug: Maraviroc 300 mg;   Behavioral: Rehabilitation therapy;   Drug: Placebo 300 mg
    Sponsors:   University of California, Los Angeles;   Burke Neurological Research Institute;   Yale University
    Recruiting
  • A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
    NCT02491099
    Condition:   HER2/Neu+ Uterine Serous Carcinoma
    Intervention:   Drug: Afatinib
    Sponsors:   Yale University;   Boehringer Ingelheim
    Recruiting
  • Multisystemic Therapy-Emerging Adults Trial
    NCT02922335
    Condition:   Antisocial Behavior
    Interventions:   Behavioral: Multisystemic Therapy for Emerging Adults;   Behavioral: Enhanced Treatment as Usual
    Sponsors:   University of Massachusetts, Worcester;   National Institute of Mental Health (NIMH);   Oregon Social Learning Center;   Connecticut Department of Children and Families;   North American Family Institute;   Court Support Services Division
    Recruiting
  • Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)
    NCT03386487
    Condition:   Cannabis Use Disorder
    Interventions:   Drug: PF 04457845;   Drug: Placebo Oral Tablet
    Sponsors:   Yale University;   Columbia University;   Johns Hopkins University;   Medical University of South Carolina
    Recruiting
  • Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence
    NCT02120365
    Condition:   Alcoholism
    Interventions:   Drug: Perampanel;   Drug: Placebo
    Sponsors:   Virginia Commonwealth University;   University of Connecticut;   Yale University
    Recruiting
  • A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 and 754111
    NCT03964233
    Condition:   Neoplasms
    Interventions:   Drug: BI 907828;   Drug: BI 754091;   Drug: BI 754111
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers
    NCT03907969
    Condition:   Advanced Malignancies
    Interventions:   Drug: AZD7648;   Drug: Pegylated liposomal doxorubicin (PLD);   Drug: Olaparib
    Sponsors:   AstraZeneca;   Parexel
    Recruiting
  • PROactive Evaluation of Function to Avoid CardioToxicity
    NCT03862131
    Conditions:   Cardiotoxicity;   Breast Cancer;   Lymphoma;   Sarcoma;   Leukemia;   Myeloma;   Lung Cancer
    Intervention:   Device: MyoStrain®
    Sponsors:   Washington University School of Medicine;   Myocardial Solutions
    Recruiting
  • Online Therapy for Posttraumatic Stress Symptoms in WTC Responders and Survivors
    NCT03154151
    Condition:   Post-Traumatic Stress Disorder
    Interventions:   Behavioral: Online Cognitive-Behavioral Therapy;   Behavioral: Online Supportive Therapy
    Sponsors:   Icahn School of Medicine at Mount Sinai;   National Institute for Occupational Safety and Health (NIOSH/CDC)
    Recruiting
  • A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
    NCT03922477
    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Atezolizumab;   Drug: Hu5F9-G4
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma
    NCT03016871
    Conditions:   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action
    NCT02900352
    Condition:   Alcohol Use Disorder
    Interventions:   Drug: Zonisamide;   Drug: Placebo
    Sponsors:   Virginia Commonwealth University;   University of Connecticut;   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   VA Connecticut Healthcare System
    Recruiting
  • Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
    NCT02503722
    Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage III Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIB Lung Non-Small Cell Cancer AJCC v7;   Stage IV Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib;   Other: Pharmacological Study;   Drug: Sapanisertib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
    NCT02453620
    Conditions:   Breast Adenocarcinoma;   Invasive Breast Carcinoma;   Metastatic Breast Carcinoma;   Metastatic Malignant Solid Neoplasm;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Unresectable Solid Neoplasm
    Interventions:   Drug: Entinostat;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Pharmacogenomic Study;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
    NCT03150693
    Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Drug: Allopurinol;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Pegylated L-Asparaginase;   Drug: Methotrexate;   Procedure: Bone Marrow Aspiration and Biopsy;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Thioguanine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Descartes-11 in Multiple Myeloma
    NCT03994705
    Condition:   Multiple Myeloma
    Interventions:   Biological: Descartes-11;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Cartesian Therapeutics
    Recruiting
  • CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
    NCT03798678
    Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Glutaminase Inhibitor CB-839 Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of LY3405105 in Participants With Advanced Cancer
    NCT03770494
    Condition:   Solid Tumor
    Intervention:   Drug: LY3405105
    Sponsor:   Eli Lilly and Company
    Recruiting
  • Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
    NCT03680560
    Conditions:   Solid Tumor;   HER-2 Protein Overexpression
    Interventions:   Biological: ACTR T Cell Product;   Drug: Trastuzumab
    Sponsor:   Unum Therapeutics Inc.
    Recruiting
  • ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
    NCT03113968
    Conditions:   Treatment Resistant Depression;   Electroconvulsive Therapy;   ECT;   Ketamine;   Psychiatric Disorder;   Depression;   Major Depressive Disorder;   Major Depressive Episode;   Unipolar Depression
    Interventions:   Procedure: electroconvulsive therapy (ECT);   Drug: Ketamine
    Sponsors:   The Cleveland Clinic;   Patient-Centered Outcomes Research Institute
    Recruiting
  • A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
    NCT03665285
    Conditions:   Advanced or Metastatic Solid Tumors;   Head and Neck Squamous Cell Carcinoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Triple Negative Breast Cancer
    Intervention:   Drug: NC318
    Sponsor:   NextCure, Inc.
    Recruiting
  • Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
    NCT03621982
    Conditions:   Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content;   Head and Neck Cancer;   Non-small Cell Lung Cancer;   Gastric Cancer;   Esophageal Cancer;   Pancreas Cancer;   Bladder Cancer;   Renal Cell Carcinoma;   Melanoma;   Triple-negative Breast Cancer;   Ovarian Cancer;   Colo-rectal Cancer
    Intervention:   Drug: ADCT-301
    Sponsor:   ADC Therapeutics S.A.
    Recruiting
  • High-quality COPD Care for People With Immune Dysfunction Through Proactive E-consults
    NCT03856879
    Conditions:   COPD;   HIV/AIDS
    Intervention:   Behavioral: Proactive E-consult
    Sponsors:   Seattle Institute for Biomedical and Clinical Research;   VA Puget Sound Health Care System;   Bronx Veterans Medical Research Foundation, Inc;   Washington D.C. Veterans Affairs Medical Center;   VA Eastern Colorado Health Care System;   University of Colorado, Denver;   VA Greater Los Angeles Healthcare System;   Atlanta VA Medical Center;   Baylor College of Medicine;   Michael Debakey Veterans Affairs Medical Center;   Yale University;   VA Connecticut Healthcare System
    Recruiting
  • Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
    NCT00351611
    Condition:   Epilepsies, Partial
    Interventions:   Drug: Lyrica (pregabalin);   Drug: placebo
    Sponsor:   Pfizer
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
    NCT03770260
    Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Ixazomib Citrate;   Drug: Pevonedistat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
    NCT02936752
    Conditions:   Blasts 21-30 Percent of Bone Marrow Nucleated Cells;   Myelodysplastic Syndrome
    Interventions:   Drug: Entinostat;   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
    NCT03102047
    Condition:   Rectal Cancer
    Intervention:   Drug: durvalumab
    Sponsor:   NSABP Foundation Inc
    Recruiting
  • Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer
    NCT03816345
    Conditions:   Advanced Malignant Neoplasm;   Autoimmune Disease;   Crohn Disease;   Dermatomyositis;   Inflammatory Bowel Disease;   Metastatic Malignant Neoplasm;   Multiple Sclerosis;   Rheumatoid Arthritis;   Sjogren Syndrome;   Systemic Lupus Erythematosus;   Systemic Scleroderma;   Ulcerative Colitis;   Unresectable Malignant Neoplasm
    Intervention:   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • M6620, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
    NCT02567422
    Conditions:   Head and Neck Squamous Cell Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7
    Interventions:   Drug: ATR Kinase Inhibitor M6620;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
    NCT02520791
    Conditions:   Follicular T-Cell Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Angioimmunoblastic T-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Angioimmunoblastic T-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Stage IB Mycosis Fungoides AJCC v7;   Stage II Mycosis Fungoides AJCC v7;   Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage III Mycosis Fungoides AJCC v7;   Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides AJCC v7
    Interventions:   Biological: Anti-ICOS Monoclonal Antibody MEDI-570;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma
    NCT03854474
    Conditions:   Advanced Urothelial Carcinoma;   Locally Advanced Urothelial Carcinoma;   Metastatic Bladder Urothelial Carcinoma;   Metastatic Urothelial Carcinoma;   Stage III Bladder Cancer AJCC v8;   Stage IIIA Bladder Cancer AJCC v8;   Stage IIIB Bladder Cancer AJCC v8;   Stage IV Bladder Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8
    Interventions:   Biological: Pembrolizumab;   Drug: Tazemetostat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
    NCT03047213
    Conditions:   Locally Advanced Bladder Urothelial Carcinoma;   Metastatic Transitional Cell Carcinoma;   Metastatic Urothelial Carcinoma;   Recurrent Bladder Carcinoma;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage IV Bladder Urothelial Carcinoma AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Sapanisertib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
    NCT03030378
    Conditions:   Metastatic Malignant Solid Neoplasm;   Unresectable Solid Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Recombinant Interleukin-12
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus
    NCT03978520
    Condition:   Systemic Lupus Erythematosus (SLE)
    Interventions:   Drug: ABBV-105;   Drug: Placebo for ABBV-105;   Drug: Upadacitinib;   Drug: Placebo for upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion
    NCT03954041
    Condition:   Brain Contusion
    Interventions:   Drug: BIIB093;   Drug: Placebo
    Sponsor:   Biogen
    Recruiting
  • Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
    NCT02971501
    Conditions:   Lung Carcinoma Metastatic in the Brain;   Lung Non-Small Cell Carcinoma
    Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
    NCT03851445
    Condition:   Previously Treated Non-Small Cell Lung Cancer
    Intervention:   Drug: Screening Platform
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer
    NCT03811015
    Conditions:   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
    NCT03793179
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
    NCT03768414
    Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
    NCT03768063
    Condition:   Cancer
    Intervention:   Drug: Atezolizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
    NCT03723928
    Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
    Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
    NCT03712605
    Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Savolitinib in Treating Participants With MET Amplified Metastatic or Unresectable Colorectal Cancer
    NCT03592641
    Conditions:   Colon Adenocarcinoma;   Colorectal Carcinoma;   Rectal Adenocarcinoma;   Stage III Colon Cancer AJCC v8;   Stage III Rectal Cancer AJCC v8;   Stage IIIA Colon Cancer AJCC v8;   Stage IIIA Rectal Cancer AJCC v8;   Stage IIIB Colon Cancer AJCC v8;   Stage IIIB Rectal Cancer AJCC v8;   Stage IIIC Colon Cancer AJCC v8;   Stage IIIC Rectal Cancer AJCC v8;   Stage IV Colon Cancer AJCC v8;   Stage IV Rectal Cancer AJCC v8;   Stage IVA Colon Cancer AJCC v8;   Stage IVA Rectal Cancer AJCC v8;   Stage IVB Colon Cancer AJCC v8;   Stage IVB Rectal Cancer AJCC v8;   Stage IVC Colon Cancer AJCC v8;   Stage IVC Rectal Cancer AJCC v8
    Intervention:   Drug: Savolitinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
    NCT03499808
    Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
    Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
    NCT03212274
    Conditions:   Advanced Malignant Solid Neoplasm;   Glioblastoma;   Recurrent Cholangiocarcinoma;   Recurrent Glioma;   Recurrent Malignant Solid Neoplasm;   WHO Grade II Glioma;   WHO Grade III Glioma
    Intervention:   Drug: Olaparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
    NCT02498613
    Conditions:   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma;   Stage III Breast Cancer AJCC v7;   Stage III Lung Non-Small Cell Cancer AJCC v7;   Stage III Lung Small Cell Carcinoma AJCC v7;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Small Cell Carcinoma AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIB Lung Non-Small Cell Cancer AJCC v7;   Stage IIIB Lung Small Cell Carcinoma AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Lung Non-Small Cell Cancer AJCC v7;   Stage IV Lung Small Cell Carcinoma AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma;   Unresectable Pancreatic Carcinoma
    Interventions:   Other: 18F-Fluoromisonidazole;   Drug: Cediranib;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Procedure: Positron Emission Tomography
    Sponsors:   National Cancer Institute (NCI);   AstraZeneca
    Recruiting
  • Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer
    NCT03304639
    Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIA Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7
    Interventions:   Biological: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
    NCT03244384
    Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
    NCT03224767
    Conditions:   BRAF V600E Mutation Present;   Papillary Craniopharyngioma
    Interventions:   Drug: Vemurafenib;   Drug: Cobimetinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
    NCT03108456
    Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
    Interventions:   Device: Orbital Atherectomy;   Device: Balloon
    Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
    Recruiting
  • Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
    NCT03008278
    Conditions:   Metastatic Esophageal Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Gastroesophageal Junction Adenocarcinoma;   Stage III Esophageal Cancer AJCC v7;   Stage III Gastric Cancer AJCC v7;   Stage IIIA Esophageal Cancer AJCC v7;   Stage IIIA Gastric Cancer AJCC v7;   Stage IIIB Esophageal Cancer AJCC v7;   Stage IIIB Gastric Cancer AJCC v7;   Stage IIIC Esophageal Cancer AJCC v7;   Stage IIIC Gastric Cancer AJCC v7;   Stage IV Esophageal Cancer AJCC v7;   Stage IV Gastric Cancer AJCC v7;   Unresectable Esophageal Carcinoma;   Unresectable Gastric Carcinoma;   Unresectable Gastroesophageal Junction Adenocarcinoma
    Interventions:   Drug: Olaparib;   Biological: Ramucirumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast Cancer
    NCT02849496
    Conditions:   Locally Advanced Unresectable Breast Carcinoma;   Metastatic Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Atezolizumab;   Drug: Olaparib;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
    NCT02761057
    Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
    NCT02734537
    Conditions:   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant;   Lip and Oral Cavity Squamous Cell Carcinoma;   p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Collection and Storage of Tissue and Blood Samples From Patients With Cancer
    NCT02474160
    Conditions:   Lymphoma;   Malignant Neoplasm;   Malignant Solid Neoplasm;   Metastatic Malignant Solid Neoplasm;   Plasma Cell Leukemia;   Plasma Cell Myeloma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma
    Intervention:   Other: Cytology Specimen Collection Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
    NCT02595931
    Conditions:   Advanced Malignant Solid Neoplasm;   Metastatic Malignant Neoplasm;   Refractory Malignant Neoplasm;   Unresectable Malignant Neoplasm
    Interventions:   Drug: ATR Kinase Inhibitor M6620;   Drug: Irinotecan;   Drug: Irinotecan Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
    NCT02314169
    Conditions:   Anal Canal Squamous Cell Carcinoma;   Metastatic Anal Canal Carcinoma;   Stage IV Anal Canal Cancer AJCC v6 and v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
    NCT02275533
    Condition:   Acute Myeloid Leukemia
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
    NCT02224781
    Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
    NCT01872975
    Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
    Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
    Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
    NCT01805076
    Conditions:   Estrogen Receptor-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
    Interventions:   Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   American College of Radiology Imaging Network
    Recruiting
  • S0820, Adenoma and Second Primary Prevention Trial
    NCT01349881
    Condition:   Colorectal Neoplasms
    Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
    Recruiting
  • Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
    NCT02567435
    Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
    NCT03258931
    Condition:   Newly Diagnosed FLT3 Mutated AML
    Interventions:   Drug: Crenolanib;   Drug: Midostaurin;   Drug: Cytarabine;   Drug: Duanorubicin
    Sponsor:   Arog Pharmaceuticals, Inc.
    Recruiting
  • Comparison of MENOPUR Liquid and Powder in Women Undergoing ART
    NCT04163458
    Condition:   Infertility
    Interventions:   Drug: MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL;   Drug: MENOPUR powder and solvent for solution for injection, 75 IU;   Other: Placebo (for MENOPUR solution for injection in pre-filled pen);   Other: Placebo (for MENOPUR powder and solvent for solution for injection)
    Sponsor:   Ferring Pharmaceuticals
    Recruiting
  • A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
    NCT03523728
    Condition:   Polycystic Kidney, Autosomal Dominant
    Interventions:   Drug: Venglustat GZ402671;   Drug: Placebo
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting
  • A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer
    NCT04069026
    Condition:   Advanced Solid Tumors
    Intervention:   Drug: BAY2416964
    Sponsor:   Bayer
    Recruiting
  • The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation
    NCT03982420
    Conditions:   Carotid Artery Diseases;   Carotid Atherosclerosis;   Carotid Stenosis;   Carotid Artery Plaque;   Carotid Disease
    Intervention:   Procedure: Transcarotid Revascularization (TCAR)
    Sponsor:   Silk Road Medical
    Recruiting
  • A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
    NCT03834584
    Condition:   Lymphoma
    Intervention:   Drug: AG-636
    Sponsor:   Agios Pharmaceuticals, Inc.
    Recruiting
  • A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors
    NCT03522142
    Condition:   Advanced Solid Tumors
    Interventions:   Drug: INCB081776;   Drug: Nivolumab
    Sponsor:   Incyte Corporation
    Recruiting
  • Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
    NCT03492151
    Condition:   Pancreatic Cyst
    Intervention:  
    Sponsors:   Ohio State University;   American College of Gastroenterology;   The National Pancreas Foundation
    Recruiting
  • This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)
    NCT03449381
    Condition:   Neoplasms
    Intervention:   Drug: BI 907828
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
    NCT03435250
    Conditions:   Advanced Solid Tumors;   Lymphoma
    Interventions:   Drug: AG-270;   Drug: docetaxel;   Drug: nab-paclitaxel;   Drug: gemcitabine
    Sponsor:   Agios Pharmaceuticals, Inc.
    Recruiting
  • Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
    NCT02688985
    Conditions:   Relapsing Multiple Sclerorsis;   Multiple Sclerosis, Primary Progressive
    Interventions:   Drug: Ocrelizumab;   Procedure: Lumbar Puncture;   Drug: Methyloprednisolone;   Drug: Antihistamine
    Sponsor:   Genentech, Inc.
    Recruiting
  • M8891 First in Human in Solid Tumors
    NCT03138538
    Condition:   Advanced Solid Tumors
    Intervention:   Drug: M8891
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Recruiting
  • A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
    NCT02667873
    Condition:   Solid Tumors
    Intervention:   Drug: SL-801
    Sponsor:   Stemline Therapeutics, Inc.
    Recruiting
  • A Study to Assess the Effects of RO6889450 in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
    NCT03669640
    Condition:   Schizophrenia, Schizoaffective Disorder
    Interventions:   Drug: RO6889450;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
    NCT03203642
    Conditions:   Autosomal Dominant Polycystic Kidney;   ADPKD
    Interventions:   Drug: Tesevatinib;   Drug: Placebo
    Sponsor:   Kadmon Corporation, LLC
    Recruiting
  • A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia
    NCT03382639
    Condition:   Schizophrenia
    Interventions:   Drug: TAK-831;   Drug: Placebo
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting
  • Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
    NCT03206450
    Conditions:   Cancer Survivor;   Osteosarcoma
    Interventions:   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
    NCT03422536
    Conditions:   Head and Neck Basaloid Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IV Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Head and Neck Cancer;   Oropharyngeal Cancer;   HNSCC;   Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
    Interventions:   Biological: Cetuximab;   Drug: Ficlatuzumab
    Sponsors:   University of Arizona;   National Cancer Institute (NCI)
    Recruiting
  • Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients With Worsening Heart Failure
    NCT03292653
    Condition:   Cardiac Failure Aggravated
    Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo;   Drug: Heavy Water;   Drug: 131-Iodine-Albumin
    Sponsor:   Sanofi
    Recruiting
  • Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
    NCT02308085
    Condition:   Early Breast Cancer
    Intervention:   Other: Endocrine therapy interruption
    Sponsors:   International Breast Cancer Study Group;   Alliance for Clinical Trials in Oncology;   Canadian Cancer Trials Group;   Breast International Group
    Recruiting
  • A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
    NCT03948763
    Conditions:   Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Pancreatic Neoplasms;   Colorectal Neoplasms
    Interventions:   Biological: V941;   Biological: Pembrolizumab
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
    NCT03444753
    Condition:   Advanced Cancer
    Interventions:   Drug: BMS-986299;   Biological: Nivolumab;   Biological: Ipilimumab
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • PF-06651600 for the Treatment of Alopecia Areata
    NCT03732807
    Condition:   Alopecia Areata
    Interventions:   Drug: PF-06651600 Induction Dose;   Drug: PF-06651600 Maintenance Dose #1;   Drug: PF-06651600 Maintenance Dose #2;   Drug: PF-06651600 Maintenance Dose #3;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Derazantinib and Atezolizumab in Patients With Urothelial Cancer
    NCT04045613
    Condition:   Urothelial Carcinoma
    Interventions:   Drug: Derazantinib;   Drug: Atezolizumab (drug supplied by Hoffmann-La Roche)
    Sponsor:   Basilea Pharmaceutica
    Recruiting
  • A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
    NCT04035135
    Condition:   Guillain-Barré Syndrome
    Interventions:   Drug: ANX005;   Drug: Intravenous immunoglobulin
    Sponsors:   Annexon, Inc.;   ResearchPoint Global;   International Centre for Diarrhoeal Disease Research, Bangladesh
    Recruiting
  • Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
    NCT03980730
    Condition:   Alzheimer Disease
    Interventions:   Drug: Azeliragon;   Drug: Placebo
    Sponsor:   vTv Therapeutics
    Recruiting
  • A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma
    NCT03875079
    Condition:   Metastatic Melanoma
    Interventions:   Drug: RO6874281;   Drug: Pembrolizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
    NCT03829501
    Conditions:   Squamous Cell Carcinoma of Head and Neck;   Non-small Cell Lung Cancer;   Hepatocellular Carcinoma;   Esophageal Cancer;   Gastric Cancer;   Melanoma;   Renal Cell Carcinoma;   Pancreatic Cancer;   Cervical Cancer;   Triple Negative Breast Cancer;   Advanced Cancer
    Interventions:   Drug: KY1044;   Drug: KY1044 and atezolizumab
    Sponsor:   Kymab Limited
    Recruiting
  • Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
    NCT03829319
    Condition:   Nonsquamous Non-small Cell Lung Cancer
    Interventions:   Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Lenvatinib;   Drug: Placebo matching lenvatinib
    Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
    Recruiting
  • Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors
    NCT03821935
    Condition:   Advanced Solid Tumors Cancer
    Interventions:   Drug: ABBV-151;   Drug: ABBV-181
    Sponsor:   AbbVie
    Recruiting
  • A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma
    NCT03783442
    Condition:   Esophageal Squamous Cell Carcinoma (ESCC)
    Interventions:   Drug: Platinum (cisplatin or oxaliplatin) + Fluorouracil (5-FU);   Drug: Platinum (cisplatin or oxaliplatin) + capecitabine;   Drug: Platinum (cisplatin or oxaliplatin) + paclitaxel
    Sponsor:   BeiGene
    Recruiting
  • A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
    NCT03726879
    Condition:   Breast Cancer
    Interventions:   Drug: Atezolizumab;   Drug: Placebo;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Trastuzumab Emtansine
    Sponsors:   Hoffmann-La Roche;   Chugai Pharmaceutical
    Recruiting
  • A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
    NCT03574571
    Condition:   Prostate Cancer
    Interventions:   Drug: Docetaxel 75 mg/m2;   Drug: Docetaxel 60 mg/m2;   Drug: Radium-223
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Bayer
    Recruiting
  • A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors
    NCT03565445
    Condition:   Advanced Solid Tumors
    Interventions:   Drug: ASP1948;   Drug: nivolumab
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
    NCT03539952
    Condition:   Wilson Disease
    Interventions:   Drug: TETA 4HCL;   Drug: Penicillamine
    Sponsor:   GMP-Orphan SAS
    Recruiting
  • A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
    NCT03448042
    Condition:   Solid Tumors
    Intervention:   Drug: BTRC4017A
    Sponsor:   Genentech, Inc.
    Recruiting
  • A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
    NCT03337698
    Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: Atezolizumab;   Drug: Cobimetinib;   Drug: RO6958688;   Drug: Docetaxel;   Drug: CPI-444;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Gemcitabine;   Drug: Linagliptin;   Drug: Tocilizumab;   Drug: Ipatasertib;   Drug: Idasanutlin
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • AVID100 in Advanced Epithelial Carcinomas
    NCT03094169
    Conditions:   Solid Tumor, Adult;   Triple Negative Breast Cancer;   Head and Neck Squamous Cell Carcinoma;   Non Small Cell Lung Cancer
    Intervention:   Drug: AVID100 IV
    Sponsor:   Formation Biologics
    Recruiting
  • A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies
    NCT03082209
    Conditions:   Advanced Solid Tumors Cancer;   Hematologic Malignancies
    Interventions:   Drug: ABBV-621;   Drug: Venetoclax;   Drug: Bevacizumab;   Drug: FOLFIRI
    Sponsor:   AbbVie
    Recruiting
  • Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults
    NCT03073967
    Condition:   HSV Infection
    Interventions:   Drug: Pritelivir;   Drug: Foscarnet
    Sponsors:   AiCuris Anti-infective Cures GmbH;   Medpace, Inc.
    Recruiting
  • A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
    NCT02848001
    Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
    Intervention:   Drug: CC-90009
    Sponsor:   Celgene
    Recruiting
  • GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3
    NCT02843035
    Condition:   Gaucher Disease Type 1-Gaucher Disease Type 3
    Intervention:   Drug: GZ402671
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting
  • An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
    NCT02754141
    Condition:   Malignant Solid Tumor
    Interventions:   Biological: BMS-986179;   Biological: Nivolumab;   Biological: rHuPH20
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • DS-3201b in Participants With Lymphomas
    NCT02732275
    Conditions:   Lymphoma, Malignant;   Non-hodgkin Lymphoma
    Intervention:   Drug: DS-3201b
    Sponsors:   Daiichi Sankyo Co., Ltd.;   Daiichi Sankyo, Inc.
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC